Opinion|Videos|January 22, 2026
Clinical Scenario: Treatment Decisions for a 53-Year-Old w/ R/R LBCL
Fact checked by: Justin Mancini
Panelists review a patient with relapsed LBCL presenting with symptomatic disease and logistical barriers to treatment access. The discussion highlights how proximity to treatment centers, work demands, and concerns about toxicity influence therapy selection. Faculty consider practical approaches to balancing efficacy, access, and quality-of-life considerations.
Advertisement
Episodes in this series
Panelists review a patient with relapsed LBCL presenting with symptomatic disease and logistical barriers to treatment access. The discussion highlights how proximity to treatment centers, work demands, and concerns about toxicity influence therapy selection. Faculty consider practical approaches to balancing efficacy, access, and quality-of-life considerations.
Advertisement
Related to this article
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.
William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.
Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
3
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
4
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
5